We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Effectiveness of antiemetic triplet therapy with aprepitant, palonosetron, and dexamethasone for gynecologic cancer patients receiving carboplatin and paclitaxel: a prospective single-arm study.
- Authors
Ito, Fuminori; Furukawa, Naoto
- Abstract
<bold>Purpose: </bold>There is no positive evidence for the efficacy of antiemetic triplet therapy with aprepitant (APR), palonosetron (PALO), and dexamethasone (DEX) for moderate emetogenic chemotherapy, especially for gynecologic malignancies. Thus, the present study evaluated the efficacy of this triplet therapy in patients receiving carboplatin and paclitaxel (CP) for gynecologic malignancy.<bold>Methods: </bold>Seventy patients with gynecologic cancer receiving CP were enrolled into a prospective single-arm study with APR (125 mg on day 1, 80 mg on days 2-3), PALO (0.75 mg), and DEX (20 mg) before initiating chemotherapy. The primary endpoint was delayed complete response (CR) rate, i.e., no vomiting and no rescue, at 24-120 h after chemotherapy administration.<bold>Results: </bold>Seventy patients were enrolled. The delayed CR rate was 97.1% (68/70). No serious adverse events were observed. Younger patient age (≤50 years) tended to be associated with a poor delayed CR rate.<bold>Conclusions: </bold>This study demonstrated a notable efficacy of antiemetic triplet therapy with APR, PALO, and DEX in female patients receiving CP. Further evaluation with a larger phase III trial is warranted.
- Subjects
CHEMOTHERAPY complications; CANCER patients; CARBOPLATIN; PACLITAXEL; DEXAMETHASONE; THERAPEUTICS; ANTIEMETICS; ANTINEOPLASTIC agents; CLINICAL trials; FEMALE reproductive organ tumors; HETEROCYCLIC compounds; ISOQUINOLINE; LONGITUDINAL method; NAUSEA; VOMITING; PHARMACODYNAMICS
- Publication
Supportive Care in Cancer, 2017, Vol 25, Issue 6, p1941
- ISSN
0941-4355
- Publication type
journal article
- DOI
10.1007/s00520-017-3607-x